title: Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.
abstract: BACKGROUND
  This is a randomized, controlled trial of preoperative chemotherapy in patients undergoing surgery for oesophageal squamous cell carcinoma (OSCC). Patients were allocated to chemotherapy, consisting of 2-4 cycles of cisplatin and etoposide, followed by surgery (CS group) or surgery alone (S group). Initial results reported only in abstract form in 1997, demonstrated an advantage for overall survival in the CS group. The results of this trial have been updated and discussed in the timeframe in which this study was performed.
  
  
  METHODS
  This trial recruited 169 patients with OSCC, 85 patients assigned to preoperative chemotherapy and 84 patients underwent immediate surgery. The primary study endpoint was overall survival (OS), secondary endpoints were disease free survival (DFS) and pattern of failure. Survival has been determined from Kaplan-Meier curves and treatment comparisons made with the log-rank test.
  
  
  RESULTS
  There were 148 deaths, 71 in the CS and 77 in the S group. Median OS time was 16 months in the CS group compared with 12 months in the S group; 2-year survival rates were 42% and 30%; and 5-year survival rates were 26% and 17%, respectively. Intention to treat analysis showed a significant overall survival benefit for patients in the CS group (P = 0.03, by the log-rank test; hazard ratio [HR] 0.71; 95%CI 0.51-0.98). DFS (from landmark time of 6 months after date of randomisation) was also better in the CS-group than in the S group (P = 0.02, by the log-rank test; HR 0.72; 95%CI 0.52-1.0). No difference in failure pattern was observed between both treatment arms.
  
  
  CONCLUSIONS
  Preoperative chemotherapy with a combination of etoposide and cisplatin significantly improved overall survival in patients with OSCC.
authors: Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. j.j.boonstra@erasmusmc.nl
authors: Jurjen J
authors: JJ
authors: Boonstra
authors: Tjebbe C
authors: TC
authors: Kok
authors: Bas Pl
authors: BP
authors: Wijnhoven
authors: Mark
authors: M
authors: van Heijl
authors: Mark I
authors: MI
authors: van Berge Henegouwen
authors: Fiebo Jw
authors: FJ
authors: Ten Kate
authors: Peter D
authors: PD
authors: Siersema
authors: Winand Nm
authors: WN
authors: Dinjens
authors: Jan Jb
authors: JJ
authors: van Lanschot
authors: Hugo W
authors: HW
authors: Tilanus
authors: Ate
authors: A
authors: van der Gaast
references: J Clin Oncol. 2007 Aug 20;25(24):3719-25
references: 17704421
references: J Clin Oncol. 2009 Oct 20;27(30):5062-7
references: 19770374
references: Semin Oncol. 1986 Sep;13(3 Suppl 3):97-103
references: 3020707
references: Nat Rev Cancer. 2003 Jun;3(6):453-8
references: 12778135
references: Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):517-26
references: 18679388
references: Cancer Cell. 2008 Oct 7;14(4):283-4
references: 18835030
references: Br J Cancer. 1996 Sep;74(6):980-4
references: 8826870
references: Lancet. 2002 May 18;359(9319):1727-33
references: 12049861
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: N Engl J Med. 2002 Nov 21;347(21):1662-9
references: 12444180
references: N Engl J Med. 1998 Dec 31;339(27):1979-84
references: 9869669
references: Stat Med. 1997 Mar 30;16(6):695-704
references: 9131757